Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

NCT04125693 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Rogaratinib (BAY1163877)
DRUG: Combination drug

Sponsor

Bayer